Samsung's Challenger to Pfizer Drug Wins European Backing

Updated on
  • Benepali is first copy of Enbrel, follows Remicade biosimilar
  • Enbrel medicine is among Pfizer's top-selling products

A drug developed by a joint venture between Samsung Biologics and Biogen Inc. was recommended for approval by the European Union’s drug regulator, threatening sales of a similar Pfizer Inc. product.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.